Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,027 total articles
NOV Inc. announced its first quarter 2026 financial results showing $2.05 billion in revenue, a 2% decrease year-over-year, with net income down to $19 million. Operational challenges due to the Middle East conflict negatively impacted revenue and profitability by approximately $54 million and $32 million respectively. Despite these setbacks, NOV s…
Performance Shipping Inc., a global tanker vessel operator, has filed its 2025 Annual Report on Form 20-F containing audited financial statements with the U.S. SEC, making it accessible for investors and shareholders.
Biomea Fusion announced positive 52-week results from its Phase 2 COVALENT-112 trial evaluating icovamenib in type 1 diabetes patients. The treatment showed a 52% increase in C-peptide levels at 12 weeks in patients diagnosed within 3 years, with durable effects preserved through 52 weeks after only a 12-week dosing period. The drug was well tolera…
Heron Therapeutics, a commercial-stage biotechnology company, will report its first quarter 2026 financial results on May 11, 2026. The company will host a conference call and webcast to discuss these results along with recent business highlights. Investors can access the call via phone or through the company's website, where an archive will be ava…
Taysha Gene Therapies announced new preclinical data demonstrating that their TSHA-102 gene therapy, based on self-complementary AAV9 delivering a miniaturized MECP2 transgene, achieves approximately 30-fold higher MeCP2 protein expression compared to a single-stranded AAV9 construct in neuronal models. These results validate the design of TSHA-102…
Lexeo Therapeutics announced multiple presentations at the 29th ASGCT Annual Meeting featuring new data on its cardiac gene therapy pipeline, including TNNI3 cardiomyopathy and Friedreich ataxia treatments, as well as advances in AAV manufacturing technology. The presentations highlight the company's innovative approaches and ongoing clinical trial…
Crinetics Pharmaceuticals announced that the European Commission has approved PALSONIFY® (paltusotine) for the treatment of acromegaly in adults, representing the first once-daily oral therapy approved in the EU. This approval is based on robust clinical data from two pivotal Phase 3 trials demonstrating efficacy, safety, and symptom improvement. W…
North American Construction Group Ltd. (NACG) will release its Q1 2026 financial results on May 13, 2026, followed by a conference call and webcast on May 14, 2026. The company provides heavy civil construction and mining services across Australia, Canada, and the U.S., serving mining, resource, and infrastructure construction markets.
Cabaletta Bio announced multiple presentations at the ASGCT 2026 Annual Meeting showcasing clinical, translational, and manufacturing data on rese-cel, their investigational CAR T cell therapy for autoimmune diseases. Highlights include early clinical data without preconditioning, automated manufacturing advances, and single-cell profiling across v…
Auddia Inc., a US-based technology company specializing in AI-driven audio identification and classification, announced the closing of its $12 million public offering. The offering included common stock and warrants, aiming to support the company's working capital and general corporate purposes as it advances its audio AI platform and music promoti…
Aclaris Therapeutics announced it will release the full results of its Phase 1a trials for its anti-TSLP/IL-4R bispecific antibody ATI-052 and disclose the lead indication chosen for its ITK/JAK3 inhibitor ATI-2138. The company plans a webcast and conference call on April 28, 2026, to discuss these data and updates ahead of market open.
First Bank reported first quarter 2026 net income of $7.6 million, down from $9.4 million in the prior year period, driven by elevated credit loss expenses primarily related to its small business portfolio. The bank experienced modest growth in loans and deposits and maintained a strong and stable net interest margin of 3.69%. Despite increased non…
Dyne Therapeutics announced upcoming presentation of new preclinical data demonstrating its FORCE platform's ability to cross the blood-brain barrier and effectively knockdown MAPT RNA in the central nervous system of nonhuman primates and mice. This breakthrough highlights the platform's potential applications beyond neuromuscular diseases into ne…
Voyager Therapeutics announced eight presentations at ASGCT 2026 including a late-breaking oral presentation highlighting the safety and pharmacology of VY1706, its IV-delivered tau-silencing gene therapy targeting Alzheimer's disease. The company plans to submit an IND in Q2 2026 and initiate first-in-human dosing in the second half of 2026. Addit…
Editas Medicine announced upcoming presentations of new preclinical data for EDIT-401, their lead in vivo CRISPR gene editing candidate, demonstrating its potential as a transformative treatment for hyperlipidemia and related cardiovascular diseases. These presentations will occur across multiple prestigious scientific conferences in May 2026, high…
Montauk Renewables, a NASDAQ-listed renewable energy company, announced its first quarter 2026 earnings conference call to be held on May 7, 2026. The company specializes in converting biogas into renewable natural gas and renewable electricity, operating multiple projects across several U.S. states. Financial results will be released prior to the …
Robin Energy Ltd., a global energy transportation ship-owning company, completed an oversubscribed tender offer for up to 1,000,000 common shares at $3.00 per share. Approximately 1.9 million shares were tendered, with a proration factor of 42.069% applied. The company plans to pay for accepted shares promptly and highlights that the offer was made…
Marex Group plc announced that it will release its fiscal 2026 first quarter results before market open on May 6, 2026, followed by a conference call to discuss the results. The company provides market access and liquidity services across global commodity and financial markets through clearing, execution, market making, and investment solutions.
Hillman Solutions Corp. reported a 3.0% increase in net sales to $370.1 million in Q1 2026 but recorded a net loss of $4.7 million. The company completed acquisitions of Campbell Chain & Fittings and Delaney Hardware, expanding its Industrial MRO and Pro Distribution presence. It raised its full-year 2026 net sales guidance while maintaining Adjust…
XCharge, a Nasdaq-listed company specializing in electric vehicle charging and energy storage solutions, announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2025. The report is accessible on the SEC and company websites, with hard copies available for shareholders upon request.
Gulf Resources, Inc., a leading Chinese bromine and crude salt manufacturer, announced receipt of a Nasdaq delinquency notice due to its failure to timely file its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company has 60 days to submit a plan to regain compliance, with potential relief until October 12, 2026, if ac…
Sana Biotechnology announced that its preclinical data on SG293, a novel in vivo CAR T cell therapy using proprietary fusogen technology, will be presented orally at the ASGCT 2026 Annual Meeting. SG293 targets CD8+ T cells to generate CD19-directed CAR T cells with precision, aiming to treat both B-cell cancers and autoimmune diseases while minimi…
Cellectis announced new research on its TALE-based epigenetic editing approach showcased at the ASGCT annual meeting. This method achieves over 90% sustained gene knock-down in two key genes without creating DNA breaks or permanent sequence change, offering a potentially safer genome editing alternative. The platform expands Cellectis' gene editing…
Charlton Aria Acquisition Corporation, a Cayman Islands exempted blank check company listed on Nasdaq, announced that its Sponsor has deposited $850,000 into the trust account, granting an extension until July 25, 2026 to complete its initial business combination. This marks the utilization of the Company's option to extend the deadline by three mo…
CVRx, a medical device company specializing in neuromodulation therapies for cardiovascular diseases, announced it will report its first quarter 2026 financial and operating results after market close on May 11, 2026, followed by a conference call. The company focuses on its FDA-approved Barostim therapy for heart failure patients.
